WO2005110059A3 - Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (tfpi) - Google Patents

Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (tfpi) Download PDF

Info

Publication number
WO2005110059A3
WO2005110059A3 PCT/US2005/009097 US2005009097W WO2005110059A3 WO 2005110059 A3 WO2005110059 A3 WO 2005110059A3 US 2005009097 W US2005009097 W US 2005009097W WO 2005110059 A3 WO2005110059 A3 WO 2005110059A3
Authority
WO
WIPO (PCT)
Prior art keywords
tfpi
tissue factor
pathway inhibitor
factor pathway
admistration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/009097
Other languages
French (fr)
Other versions
WO2005110059A2 (en
Inventor
Abla Creasy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2005244249A priority Critical patent/AU2005244249A1/en
Priority to EP05777406A priority patent/EP1729791A2/en
Priority to BRPI0508992-1A priority patent/BRPI0508992A/en
Priority to MXPA06010587A priority patent/MXPA06010587A/en
Priority to CA002560103A priority patent/CA2560103A1/en
Priority to US10/593,135 priority patent/US20080286279A1/en
Priority to JP2007504145A priority patent/JP2007532486A/en
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of WO2005110059A2 publication Critical patent/WO2005110059A2/en
Priority to IL178115A priority patent/IL178115A0/en
Priority to TNP2006000295A priority patent/TNSN06295A1/en
Anticipated expiration legal-status Critical
Priority to NO20064674A priority patent/NO20064674L/en
Publication of WO2005110059A3 publication Critical patent/WO2005110059A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Methods for prophylactically or therapeutically treating severe pneumonia involve administration of tissue factor pathway inhibitor (TFPI) or a TFPI analog to patients suffering from or at risk of developing this condition. The methods involve the use of continuous intravenous infusion of TFPI or a TFPI analog, preferably at low doses to avoid adverse side effects.
PCT/US2005/009097 2004-03-17 2005-03-17 Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (tfpi) Ceased WO2005110059A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP2007504145A JP2007532486A (en) 2004-03-17 2005-03-17 Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor
BRPI0508992-1A BRPI0508992A (en) 2004-03-17 2005-03-17 treatment of severe pneumonia by the administration of tfpi
MXPA06010587A MXPA06010587A (en) 2004-03-17 2005-03-17 Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (tfpi).
CA002560103A CA2560103A1 (en) 2004-03-17 2005-03-17 Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi)
US10/593,135 US20080286279A1 (en) 2004-03-17 2005-03-17 Treatment of Severe Community-Acquired Pneumonia by Administration of Tissue Factor Pathway Inhibitor (Tfpi)
AU2005244249A AU2005244249A1 (en) 2004-03-17 2005-03-17 Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (TFPI)
EP05777406A EP1729791A2 (en) 2004-03-17 2005-03-17 Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (tfpi)
IL178115A IL178115A0 (en) 2004-03-17 2006-09-14 Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi)
TNP2006000295A TNSN06295A1 (en) 2004-03-17 2006-09-15 Treatment of severe community - acquired pneumonia by admistration of tissue factor pathway inhibitor (tfpi)
NO20064674A NO20064674L (en) 2004-03-17 2006-10-16 Treatment of Severe Pneumonia Acquired Out of Hospital by Tissue Factor Pathway Inhibitor Administration

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55468104P 2004-03-17 2004-03-17
US60/554681 2004-03-17

Publications (2)

Publication Number Publication Date
WO2005110059A2 WO2005110059A2 (en) 2005-11-24
WO2005110059A3 true WO2005110059A3 (en) 2009-04-09

Family

ID=35394617

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/009097 Ceased WO2005110059A2 (en) 2004-03-17 2005-03-17 Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (tfpi)

Country Status (16)

Country Link
US (1) US20080286279A1 (en)
EP (1) EP1729791A2 (en)
JP (1) JP2007532486A (en)
KR (1) KR20070007336A (en)
CN (1) CN101426520A (en)
AU (1) AU2005244249A1 (en)
BR (1) BRPI0508992A (en)
CA (1) CA2560103A1 (en)
IL (1) IL178115A0 (en)
MX (1) MXPA06010587A (en)
NO (1) NO20064674L (en)
RU (1) RU2006136267A (en)
SG (1) SG150552A1 (en)
TN (1) TNSN06295A1 (en)
WO (1) WO2005110059A2 (en)
ZA (1) ZA200608413B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0916578D0 (en) * 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
CN112587522B (en) * 2020-12-03 2022-11-25 中国海洋大学 Use of tegaserod in the preparation of a medicament for the prevention or treatment of coronavirus infection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030139340A1 (en) * 2001-10-15 2003-07-24 Abla Creasey Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (TFPI)

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4603106A (en) * 1982-02-22 1986-07-29 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
JPS5896026A (en) * 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd Novel urokinase derivative, its preparation and thrombolytic agent containing the same
DE3219248A1 (en) * 1982-05-21 1983-11-24 Solco Basel AG, Birsfelden METHOD FOR OBTAINING CELL-BREATHING ACTIVE INGREDIENTS FROM CALF BLOOD
DE3380726D1 (en) * 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4511502A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4711845A (en) * 1984-08-31 1987-12-08 Cetus Corporation Portable temperature-sensitive control cassette
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US4530787A (en) * 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US4847201A (en) * 1985-02-05 1989-07-11 Cetus Corporation DNA encoding for CSF-1 and accompanying recombinant systems
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4748234A (en) * 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JPS6345230A (en) * 1986-04-01 1988-02-26 Central Glass Co Ltd Trifluoromethylbenzoyl bromide and production of bromobenzotrifluoride using said compound
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US5110730A (en) * 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
US4929700A (en) * 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US5212091A (en) * 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
US5276015A (en) * 1992-03-18 1994-01-04 Washington University Method of inhibiting microvascular thrombosis
USRE36476E (en) * 1992-03-18 1999-12-28 Washington University Method of inhibiting microvascular thrombosis
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US5589359A (en) * 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
JP3571378B2 (en) * 1994-09-30 2004-09-29 扶桑薬品工業株式会社 Infectious disease diagnostic probe
US5914316A (en) * 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
US5569644A (en) * 1995-05-18 1996-10-29 The Lubrizol Corporation Additive combinations for lubricants and functional fluids
US5612363A (en) * 1995-06-02 1997-03-18 Berlex Laboratories, Inc. N,N-di(aryl) cyclic urea derivatives as anti-coagulants
US6242414B1 (en) * 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
US5888968A (en) * 1995-06-07 1999-03-30 Chiron Corporation TFPI formulation
CA2223745C (en) * 1995-06-07 2004-03-16 Chiron Corporation Method of solubilizing, purifying, and refolding protein
US5885781A (en) * 1995-06-07 1999-03-23 Chiron Corporation Regulation of cytokine synthesis and release
US5902582A (en) * 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
US6011136A (en) * 1995-11-21 2000-01-04 Novartis Ag Cyclopeptolides
US5736364A (en) * 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
AU706582B2 (en) * 1996-03-25 1999-06-17 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Angiogenic inhibitor containing tissue factor pathway inhibitor
US5977057A (en) * 1996-05-08 1999-11-02 The University Of Vermont And State Agricultural College Thrombosis prophylaxis for factor VLEIDEN carriers
US5981471A (en) * 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
CZ298429B6 (en) * 1997-04-28 2007-10-03 Eli Lilly And Company Stable lyophilized formulation
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6824997B1 (en) * 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
CN1324244A (en) * 1998-10-22 2001-11-28 伊莱利利公司 Methods for treating sepsis
CA2351470A1 (en) * 1998-11-20 2000-06-02 Charles Jack Fisher Method of treating viral hemorrhagic fever
JP2003530819A (en) * 1999-06-14 2003-10-21 ノボ ノルディスク アクティーゼルスカブ FVIIa / TF activity inhibiting compounds
US6294648B1 (en) * 1999-07-20 2001-09-25 Bayer Corporation Protein having proteinase inhibitor activity
US6180607B1 (en) * 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
CZ20021186A3 (en) * 1999-10-04 2002-11-13 Chiron Corporation Pharmaceutical preparations containing stabilized liquid polypeptide
CA2400187A1 (en) * 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives
DE10022092A1 (en) * 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilized protein preparation and process for its preparation
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
WO2002102325A2 (en) * 2001-02-28 2002-12-27 Griffin John H Plasma glucosylceramide deficiency as risk factor for thrombosis and modulator of anticoagulant protein c
EP1383885A4 (en) * 2001-04-04 2005-11-30 American Diagnostica Inc Method of preparation of stabilized thrombin-activatable fibrinolysis inhibitor (tafi) and methods of use thereof
DE10132307A1 (en) * 2001-07-06 2003-01-30 Aventis Behring Gmbh Pharmaceutical preparation for inhalation of antithrombin in inflammatory lung diseases and ARDS
US20020198138A1 (en) * 2002-06-07 2002-12-26 Macias William Louis Combination therapy for the treatment of inflammatory and respiratory diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030139340A1 (en) * 2001-10-15 2003-07-24 Abla Creasey Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (TFPI)
US20030139339A1 (en) * 2001-10-15 2003-07-24 Abla Creasey Treatment of severe pneumonia by administration of tissue factor pathway inhibitor ( TFPI)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CAMEROTA, A.J. ET AL.: "Delayed Treatment with Recombinant Human Tissue Factor Pathway Inhibitor Improves Survival in Rabbits with Gram-Negative Peritonitis .", JOURNAL OF INFECTIOUS DISEASES, vol. 177, 1998, pages 668 - 676, XP002416386 *
CREASEY, A.A. ET AL.: "Tissue Factor Pathway Inhibitor Reduces Mortality from Escherichia coli Septic Shock", JOURNAL OF CLINICAL INVESTIGATION, vol. 91, 1993, pages 2850 - 2860, XP000615301 *
SCHULTZ, M.J. ET AL.: "Anticoagulant Therapy for Acute Lung Injury or Pneumonia", CURRENT DRUG TARGETS, vol. 4, 2003, pages 315 - 321, XP008116845 *

Also Published As

Publication number Publication date
BRPI0508992A (en) 2007-09-04
WO2005110059A2 (en) 2005-11-24
CN101426520A (en) 2009-05-06
US20080286279A1 (en) 2008-11-20
EP1729791A2 (en) 2006-12-13
NO20064674L (en) 2006-11-29
ZA200608413B (en) 2008-06-25
TNSN06295A1 (en) 2007-12-03
KR20070007336A (en) 2007-01-15
CA2560103A1 (en) 2005-11-24
AU2005244249A1 (en) 2005-11-24
MXPA06010587A (en) 2007-03-29
JP2007532486A (en) 2007-11-15
SG150552A1 (en) 2009-03-30
RU2006136267A (en) 2008-04-27
IL178115A0 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
WO2003032904A3 (en) Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)
TNSN07413A1 (en) Use of tfpi to treat severe bacterial infections
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
WO2007022101A3 (en) Treatment of diseases by subcutaneous administration of a vegf antagonist
WO2009034134A3 (en) Use of natriuretic peptides for treating angioedema syndromes
WO2006037031A3 (en) Formulations and methods for treatment of inflammatory diseases
WO2009039397A3 (en) Substituted amides, methods of making, use thereof for the treatment of diseases such as cancer
WO2007145941A3 (en) Administration of anti-cd3 antibodies in the treatment of autoimmune diseases
WO2006053160A3 (en) Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases
BRPI0111591B8 (en) compound, pharmaceutical composition, and uses of a compound
WO2005072045A3 (en) The combined use of glp-1 agonists and gastrin for regulating blood glucose levels
WO2003079991A3 (en) Method for administration of growth hormone via pulmonary delivery
WO2008045378A3 (en) Treatment of infant hyperbilirubinemia using low dosages of stannsoporfin
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
WO2008032222A3 (en) Treatment of vertigo with acetyl-l-leucine
WO2004087880A8 (en) Compounds and their use to treat diabetes and related disorders
WO2005115432A3 (en) Treatment of ocular diseases and disorders using lantibiotic compositions
TW200616644A (en) Medicine for prevention or treatment of diabetes
WO2005110059A3 (en) Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (tfpi)
WO1999045909A3 (en) Use of nitrone compounds for the inhibition of angiogenesis
WO2006113360A3 (en) Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor(tfpi)
WO2005123777A3 (en) Method of treating granuloma annulare or sarcoid
WO2006079625A3 (en) Medicaments for the prevention or treatment of heart failure comprising administration of an anticholinergic
WO2005020968A3 (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
IL146962A0 (en) Aminotetralin derivatives for the therapy of cardiovascular diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2007504145

Country of ref document: JP

Ref document number: 178115

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2560103

Country of ref document: CA

Ref document number: PA/a/2006/010587

Country of ref document: MX

Ref document number: 12006501818

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005244249

Country of ref document: AU

Ref document number: 549973

Country of ref document: NZ

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005777406

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006/08413

Country of ref document: ZA

Ref document number: 200608413

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1020067021122

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2005244249

Country of ref document: AU

Date of ref document: 20050317

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005244249

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006136267

Country of ref document: RU

Ref document number: DZP2005000511

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 200580014406.4

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005777406

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067021122

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0508992

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 10593135

Country of ref document: US